Reactivation of Hepatitis B Infection during anticancer therapy Maciej Jabłkowski, Jolanta Białkowska Medical Science Review - Hepatologia 2011; 11 37-40 aaICID: 970912
Article type: Review article
IC™ Value: 3.40
Abstract provided by Publisher
Hepatitis B virus (HBV) is a major cause of chronic liver disease worldwide. HBV
reactivation is well-described often fatal complication which is caused by anticancer or immunosuppressive
treatments is thoroughly described, and is most widely reported in patients who
have chronic HBV infection, when hepatitis B surface antigen (HBsAg) is positive. However,
reactivation can also occur in patients who have prior resolved HBV infection, in whom HBsAg
is negative but antibody to hepatitis B core antigen is positive. The antiviral drugs lamivudine,
entecavir and tenofovir are highly efficacious in preventing HBV reactivation in these circumstances.
This article focuses on the current evidence that supports these recently revised
clinical recommendations along with a review of the risk factors for reactivation, suggested
monitoring, and preventative interventions.